REG seek to:
- Facilitate regulatory compliance for all FCA-approved Insurance intermediaries, on a non-repetitive cost effective basis.
- Identify and implement new web-based mechanisms to save their Members time and money, whilst reducing their exposure to Regulatory risk.
- Facilitate business dealings between and among their Members to drive business efficiencies and revenue recognition.
News from Disruptive Capital GP Limited
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc
21 May 2021Brooklyn, NY – May 21, 2021 – Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced...
One of the UK’s largest traffic signal maintenance contracts awarded to Telent
18 May 2021Warwick, U.K., 18 May 2021 – Critical digital infrastructure specialist Telent has been awarded a contract to maintain West Yorkshire’s traffic signals, the largest contract of its kind. Telent is responsible for the maintenance, fault rectification and repair of 1,600 sites over a geographical area covering 2,029 km². The sites include assets such as traffic signals, lights, vehicle detectors and monitors, and other roadside assets.
Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy
11 May 2021BROOKLYN, N.Y. – May 11, 2021 – Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced...
Brooklyn Immunotherapeutics (BTX) Soars After Entering Into An Agreement with Lincoln Park Capital Fund
03 May 2021Brooklyn Immunotherapeutics (BTX) entered into a Purchase Agreement and a Registration Rights Agreement on April 26, 2021 with Lincoln Park Capital Fund...
Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform
29 April 2021Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders...